Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Chimiothérapie avec ou sans radiothérapie ou chirurgie dans le traitement des participants atteints d'un cancer oligométastatique de l'œsophage ou de l'estomac

5 octobre 2026 mis à jour par: M.D. Anderson Cancer Center

Un essai randomisé comparant la radiothérapie locale précoce +/- la chirurgie à la thérapie systémique pour les patients atteints d'un cancer de l'œsophage ou de l'estomac avec oligométastases

This phase II trial studies how well chemotherapy with or without radiation or surgery works in treating participants with esophageal or gastric cancer that has spread to less than 3 places in the body (oligometastatic). Drugs used in chemotherapy, such as fluorouracil and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Surgery, such as complete surgical resection, may stop the spread of tumor cells by surgically removing organs or tumors. Giving chemotherapy with radiation or surgery may work better than chemotherapy alone in treating participants with oligometastatic esophageal or gastric cancer.

Aperçu de l'étude

Description détaillée

PRIMARY OBJECTIVES:

I. To evaluate whether esophageal or gastric patients with oligometastatic cancer without disease progression after first line chemotherapy therapy will demonstrate improved overall survival (OS) with early local therapy (concurrent chemotherapy/radiation and surgery).

SECONDARY OBJECTIVES:

I. Assess the relationships between progression-free survival and overall survival between both treatment arms.

II. Report local control, loco-regional control. III. Report time to progression of distant metastases. IV. Report toxicity.

OUTLINE:

Participants receive induction chemotherapy for a minimum of 6 cycles and a maximum of 8 cycles in the absence of disease progression or unacceptable toxicity. Participants are then randomized to 1 of 2 groups.

GROUP I (MAINTENANCE CHEMOTHERAPY): Participants receive fluorouracil and capecitabine per instructions of the treating physician in the absence of disease progression or unacceptable toxicity.

GROUP II (LOCAL THERAPY): Participants receive fluorouracil and capecitabine and undergo radiation therapy (RT) per instructions of the treating physician in the absence of disease progression or unacceptable toxicity. Participants may also undergo surgery to some or all of the remaining sites of disease as is clinically prudent and indicated by treating physician.

After completion of study treatment, participants are followed up at 4-8 weeks, 2-3 months, every 3-6 months for up to 3 years, and then every 6-12 months thereafter.

Type d'étude

Interventionnel

Inscription (Estimé)

100

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Texas
      • Houston, Texas, États-Unis, 77030
        • Recrutement
        • M D Anderson Cancer Center
        • Contact:
          • Quynh-Nhu Nguyen
          • Numéro de téléphone: 713-563-2300
        • Chercheur principal:
          • Quynh-Nhu Nguyen

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 79 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • The patient has a pathologic diagnosis of tumor biopsy or FNA of esophageal or gastric cancer of adenocarcinoma histology

  • The patient is staged with EGD and PET/CT scan.

  • The patient has three or less observable metastatic lesions. Patients may have three or less radiographically visible metastatic lesions at diagnosis or if have regressed to three or less metastatic lesions after induction chemotherapy at time of randomization. The patient must have pathologic confirmation and or radiologically visible disease. For esophageal tumors, the maximal dimension of the primary tumor may not provide reproducible measurements for RECIST and may not be visible on CT or PET/CT at diagnosis or after induction chemotherapy. Accordingly, patients are eligible regardless of the imaging measurements of the primary tumor. Additionally, in patients with non-measurable metastases, patients are eligible if there is pathology confirming metastases from a distant site. However, biopsy of a metastatic site is not required if there are visible metastases on imaging (such as ultrasound, diagnostic CT , EUS, PET/CT).

    • The patient has three or less observable metastatic lesions by diagnostic scans (CT scan, PET/CT, eEndoscopic ultrasound, MRI, or bone scan). Metastatic lesions include distant M1 lymph node group; which will be counted as one site (M1 metastatic lymph nodes to include cervical, mediastinal, gastric, retroperitoneal lymph nodes will be counted as one lesion).
    • Osseous metastases or visceral metastases will each count as one metastatic site.
    • Each CNS metastases will count as one metastatic site.
    • Satellite lesions in the primary esophageal malignancy such as skipped esophageal primaries are not considered metastatic sites. Symptomatic metastatic sites can be treated locally prior to randomization or by palliative radiation.
    • Symptomatic metastatic sites may be treated with radiation or surgery prior to enrollment.
  • Patient ECOG of 0-2, with life expectancy of at least 6 months

  • Patients age >18 yrs old but <80 yrs old and signed informed consent

  • Women of child-bearing age must have pregnancy test at time of enrollment, agree to use of adequate contraception (birth control hormone or barrier method) for the duration of the study and for six months after discontinuation of systemic agents.

Exclusion Criteria:

  • Patients with prior chemotherapy or radiation therapy for their diagnosis of esophageal or gastric cancer. Patients with prior radiation therapy to same site for another diagnosis of cancer. Note: Patients may receive palliative radiation to their symptomatic sites of metastases but not definitive local therapy to esophageal or gastric primary prior to randomization. All patients may be enrolled on protocol then start systemic therapy; if they do not have evidence of disease progression at re-staging following initial therapy, they may be randomized.

  • Patients with fistula documented radiographically or by EDG/EUS, EBUS.

  • Patients with life expectancy less than 6 months, ECOG >3

  • Female patients who are pregnant confirmed by bHCG lab test.

  • Patient has history of uncontrolled angina, congestive heart failure or recent MI within 6 months.

  • Nursing females

  • Patients in poor nutritional state

  • Patients with:

    • Severely depressed bone marrow function
    • Potentially serious infections
    • Known hypersensitivity to 5-fluorouracil
    • Known or suspected to have a dihydropyrimidine dehydrogenase deficiency (as these patients are at a greater risk of experiencing symptoms of toxicity)

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Group I (maintenance chemotherapy)

Participants receive fluorouracil and capecitabine per instructions of the treating physician in the absence of disease progression or unacceptable toxicity.

Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.

Autres noms:
  • Xeloda
  • Ro 09-1978/000

Receive induction chemotherapy

Autres noms:
  • Chimio
  • Chimiothérapie (NOS)
  • Chimiothérapie, Cancer, Général

Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.

Autres noms:
  • 5-FU
  • 5-Fluracil
  • Fluracil
  • 5-Fluoro-2,4(1H, 3H)-pyrimidinedione
  • 5-Fluorouracile
  • AccuSite
  • Carac
  • Uracile fluoré
  • Fluouracil
  • Flurablastine
  • Fluracédyl
  • Flurill
  • Fluroblastine
  • Ribofluor
  • Ro 2-9757
  • Ro-2-9757
Expérimental: Group II (local therapy)

Participants receive fluorouracil and capecitabine and undergo RT per instructions of the treating physician in the absence of disease progression or unacceptable toxicity. Participants may also undergo surgery to some or all of the remaining sites of disease as is clinically prudent and indicated by treating physician.

Undergo surgery

Undergo RT

Autres noms:
  • Radiothérapie du cancer
  • Irradier
  • Irradié
  • Radiation
  • Radiothérapie
  • RT
  • Thérapie, Radiation
  • irradiation
  • RADIOTHÉRAPIE

Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.

Autres noms:
  • Xeloda
  • Ro 09-1978/000

Receive induction chemotherapy

Autres noms:
  • Chimio
  • Chimiothérapie (NOS)
  • Chimiothérapie, Cancer, Général

Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.

Autres noms:
  • 5-FU
  • 5-Fluracil
  • Fluracil
  • 5-Fluoro-2,4(1H, 3H)-pyrimidinedione
  • 5-Fluorouracile
  • AccuSite
  • Carac
  • Uracile fluoré
  • Fluouracil
  • Flurablastine
  • Fluracédyl
  • Flurill
  • Fluroblastine
  • Ribofluor
  • Ro 2-9757
  • Ro-2-9757

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Overall survival (OS)
Délai: Up to 6 years

OS distributions in the two arms will be estimated by the method of Kaplan and Meier. Bayesian piecewise exponential regression will be used to assess the relationships between each of OS and PFS, and patients' covariates and treatment arm.

Up to 6 years

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Local progression-free survival (PFS)
Délai: Up to 6 years

PFS distributions in the two arms will be estimated by the method of Kaplan and Meier. Bayesian piecewise exponential regression will be used to assess the relationships between each of OS and PFS, and patients' covariates and treatment arm.

Up to 6 years
Distant PFS
Délai: Up to 6 years

PFS distributions in the two arms will be estimated by the method of Kaplan and Meier. Bayesian piecewise exponential regression will be used to assess the relationships between each of OS and PFS, and patients' covariates and treatment arm.

Up to 6 years
Incidence of adverse events
Délai: Up to 6 years

Graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.

Up to 6 years
Time to local or regional disease recurrence
Délai: Up to 6 years

To be analyzed by Bayesian piecewise regression to assess their relationships with treatment arm and prognostic covariates.

Up to 6 years

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Time to local disease recurrence
Délai: Up to 6 years

To be analyzed by Bayesian piecewise regression to assess their relationships with treatment arm and prognostic covariates.

Up to 6 years
Time to disease progression
Délai: Up to 6 years

To be analyzed by Bayesian piecewise regression to assess their relationships with treatment arm and prognostic covariates.

Up to 6 years

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Quynh-Nhu Nguyen, M.D. Anderson Cancer Center

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

19 février 2018

Achèvement primaire (Estimé)

31 décembre 2026

Achèvement de l'étude (Estimé)

31 décembre 2026

Dates d'inscription aux études

Première soumission

18 mai 2017

Première soumission répondant aux critères de contrôle qualité

18 mai 2017

Première publication (Réel)

19 mai 2017

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

6 octobre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

5 octobre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner